semaglutide compounding news november 2025 Drug compounders sue FDA over declaration ending Wegovy shortage Novo Nordisk further lowers prices – Patients Cut Off From Cheaper

At HormoneSynergy Clinic, we use medication thoughtfully when it is appropriate

Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors

the right to request restrictions on certain disclosures

Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies